JP2012523243A5 - - Google Patents

Download PDF

Info

Publication number
JP2012523243A5
JP2012523243A5 JP2012505149A JP2012505149A JP2012523243A5 JP 2012523243 A5 JP2012523243 A5 JP 2012523243A5 JP 2012505149 A JP2012505149 A JP 2012505149A JP 2012505149 A JP2012505149 A JP 2012505149A JP 2012523243 A5 JP2012523243 A5 JP 2012523243A5
Authority
JP
Japan
Prior art keywords
promoter
tumor
stem cell
cytotoxic protein
coding region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012505149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012523243A (ja
JP5727458B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/054844 external-priority patent/WO2010119039A1/en
Publication of JP2012523243A publication Critical patent/JP2012523243A/ja
Publication of JP2012523243A5 publication Critical patent/JP2012523243A5/ja
Application granted granted Critical
Publication of JP5727458B2 publication Critical patent/JP5727458B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012505149A 2009-04-13 2010-04-13 改変間葉系幹細胞及びそれを使用した腫瘍の治療方法 Active JP5727458B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16878709P 2009-04-13 2009-04-13
US61/168,787 2009-04-13
PCT/EP2010/054844 WO2010119039A1 (en) 2009-04-13 2010-04-13 Engineered mesenchymal stem cells and method of using same to treat tumors

Publications (3)

Publication Number Publication Date
JP2012523243A JP2012523243A (ja) 2012-10-04
JP2012523243A5 true JP2012523243A5 (enExample) 2013-05-23
JP5727458B2 JP5727458B2 (ja) 2015-06-03

Family

ID=42270435

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012505149A Active JP5727458B2 (ja) 2009-04-13 2010-04-13 改変間葉系幹細胞及びそれを使用した腫瘍の治療方法

Country Status (12)

Country Link
US (2) US9434925B2 (enExample)
EP (1) EP2419113B1 (enExample)
JP (1) JP5727458B2 (enExample)
KR (1) KR20120088542A (enExample)
CN (1) CN102695517B (enExample)
AU (1) AU2010237130B2 (enExample)
BR (1) BRPI1013771A2 (enExample)
CA (1) CA2758120C (enExample)
IL (1) IL215581A0 (enExample)
RU (1) RU2539099C2 (enExample)
SG (1) SG175127A1 (enExample)
WO (1) WO2010119039A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US20130171115A1 (en) * 2011-12-30 2013-07-04 Gang Li Cell-mediated gene therapy for cancer using mesenchymal stem cells expressing a suicide gene
CN104160027B (zh) * 2012-02-01 2016-06-22 浦项工科大学校产学协力团 同时表达十二聚体trail及hsv-tk自杀基因的载体及利用其的抗癌干细胞治疗剂
US20130203166A1 (en) * 2012-02-06 2013-08-08 Protobios Llc Stimulation of multipotency of mesenchymal stem cells by chemokine ccl5
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
ES2884598T3 (es) * 2012-11-05 2021-12-10 Regeneron Pharma Animales no humanos modificados genéticamente y métodos de uso de los mismos
US10472647B2 (en) 2012-12-21 2019-11-12 The Administrators Of The Tulane Educational Fund Primary mesenchymal stem cells as a vaccine platform
WO2015100268A1 (en) * 2013-12-23 2015-07-02 The Regents Of The University Of California Mesenchymal stem cells for targeted cancer therapy
WO2015108856A2 (en) * 2014-01-17 2015-07-23 Wake Forest University Health Sciences Methods for enhancing the delivery of active agents
WO2016026854A2 (en) * 2014-08-18 2016-02-25 Apceth Gmbh & Co. Kg Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
WO2016065330A1 (en) * 2014-10-24 2016-04-28 Aladar Szalay Combination immunotherapy approach for treatment of cancer
CN104622903B (zh) * 2015-01-20 2018-10-09 奥思达干细胞有限公司 抗恶性黑色素瘤的干细胞制剂及其制备方法
JP6734283B2 (ja) 2015-01-21 2020-08-05 フレッド ハッチンソン キャンサー リサーチ センター 遺伝子治療用ポイントオブケア及び/又はポータブルプラットフォーム
WO2016138340A1 (en) * 2015-02-27 2016-09-01 Saint Louis University Tumor suppressor sall1 as a therapeutic agent for treating cancer
ES2750008T3 (es) 2015-02-27 2020-03-24 Apceth Gmbh & Co Kg Células madre mesenquimatosas modificadas genéticamente que expresan klotho
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
WO2017007994A1 (en) 2015-07-08 2017-01-12 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
EA201800148A1 (ru) 2015-08-11 2019-01-31 Калиди Биотерапьютикс, Инк. Оспенная вакцина для лечения рака
WO2017036925A1 (en) * 2015-08-28 2017-03-09 Apceth Gmbh & Co. Kg Mesenchymal stem cells for the treatment of metastatic liver disease
CN111569090A (zh) 2016-01-15 2020-08-25 美国基因技术国际有限公司 用于活化γ-δ T细胞的方法和组合物
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Hivワクチン接種および免疫療法
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
EP3462883B1 (en) * 2016-06-07 2023-08-16 The Pacific Heart, Lung,&Blood Institute Compositions and their use in treating cancer
US11976292B2 (en) 2016-06-08 2024-05-07 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
EP3481418A4 (en) 2016-07-08 2020-03-11 American Gene Technologies International Inc. PRE-IMMUNIZATION AND IMMUNOTHERAPY OF HIV
US11583562B2 (en) 2016-07-21 2023-02-21 American Gene Technologies International Inc. Viral vectors for treating Parkinson's disease
CA3042360A1 (en) 2016-11-03 2018-05-11 Exostem Biotec Ltd. Mesenchymal stem cells populations, their products, and use thereof
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
JP2020512815A (ja) 2017-04-03 2020-04-30 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド フェニルケトン尿症を処置するための組成物および方法
JP2020516654A (ja) 2017-04-13 2020-06-11 センティ バイオサイエンシズ インコーポレイテッド 組み合わせがん免疫療法
WO2018232359A1 (en) 2017-06-16 2018-12-20 American Gene Technologies International Inc. Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
US11246890B2 (en) 2018-04-03 2022-02-15 The Board Of Trustees Of The Leland Stanford Junior University Systemic targeting of inflammatory sites and enhanced immunomodulatory function by introducing the chimeric antigen receptor (CAR) into mesenchymal stem cells for inflammatory and autoimmune diseases
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
JP2021526865A (ja) * 2018-06-14 2021-10-11 ロマ・リンダ・ユニヴァーシティ 急性骨髄性白血病の処置のための操作された造血幹細胞
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
TW202035685A (zh) 2018-10-17 2020-10-01 美商聖堤生物科技股份有限公司 組合癌症免疫療法
US11352646B2 (en) 2018-11-05 2022-06-07 American Gene Technologies International Inc. Vector system for expressing regulatory RNA
CN113271955A (zh) 2018-11-06 2021-08-17 卡利迪生物治疗有限公司 用于细胞介导的溶瘤病毒疗法的增强的系统
US20220241337A1 (en) * 2019-02-22 2022-08-04 The Trustees Of Columbia University In The City Of Newyork Preparing tissues for delivery of therapeutic and diagnostic agents and delivering the agents
SG10201902002SA (en) * 2019-03-06 2020-10-29 Nat Univ Singapore Non-viral modification of mesenchymal stem cells
US20220288129A1 (en) * 2019-08-23 2022-09-15 Orbsen Therapeutics Limited Compositions for monocyte and macrophage polarization and methods of use
EP4240323A1 (en) 2020-11-06 2023-09-13 AATEC Medical GmbH A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
EP3995130A1 (en) 2020-11-06 2022-05-11 JunctuCell Biomed Manufacturing GmbH A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265564B1 (en) * 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
US7098185B2 (en) * 1998-05-18 2006-08-29 University College London Polypeptide hormone phosphatonin
AU2001265187A1 (en) * 2000-05-30 2001-12-11 Baylor College Of Medicine Chimeric viral vectors for gene therapy
WO2002069953A1 (en) * 2001-03-01 2002-09-12 The Board Of Regents Of The University Of Texas System Methods of treating lung inflammation
US20030165579A1 (en) * 2002-02-27 2003-09-04 Chih-Hui Lin Euphorbia antiquorum extract, a pharmaceutical composition containing the same and methods for treatment of cancers
DE60319240D1 (de) * 2003-12-19 2008-04-03 Charite Universitaetsmedizin Verwendung von Liganden von CD52 Antigen zur Behandlung von soliden Tumoren und von Knochenkrebserkrankungen
JP2006194752A (ja) * 2005-01-14 2006-07-27 Sumitomo Metal Mining Co Ltd X線回折測定における試料固定方法および試料固定具
KR101022401B1 (ko) * 2005-09-29 2011-03-15 아주대학교산학협력단 자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물
AU2008260651B2 (en) 2007-05-24 2014-06-12 Apceth Gmbh & Co. Kg CD34 stem cell-related methods and compositions

Similar Documents

Publication Publication Date Title
RU2011146048A (ru) Сконструированные мезенхимальные стволовые клетки и способ их применения для лечения опухолей
Howells et al. Oncolytic viruses—interaction of virus and tumor cells in the battle to eliminate cancer
Deng et al. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9
Shi et al. Engineered mesenchymal stem/stromal cells against cancer
Power et al. Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer
Yin et al. Modulation of the intratumoral immune landscape by oncolytic herpes simplex virus virotherapy
JP2008056679A5 (enExample)
JP2024045608A (ja) 制御性rnaを発現させるためのベクターシステム
EP4378487A3 (en) Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
JP2012010710A5 (enExample)
CA2640528A1 (en) Oncolytic adenoviruses for cancer treatment
Feng et al. Stabilization of G-quadruplex DNA and inhibition of Bcl-2 expression by a pyridostatin analog
Cao et al. Gene therapy for hepatocellular carcinoma based on tumour-selective suicide gene expression using the alpha-fetoprotein (AFP) enhancer and a housekeeping gene promoter
Patil et al. Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients
Bilsland et al. Virotherapy: cancer gene therapy at last?
Lucas et al. Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancer
JP2015506697A (ja) 12量体trail及びhsv−tk自殺遺伝子を同時に発現するベクター並びにそれを用いた抗癌幹細胞治療剤
JP2013530965A5 (enExample)
Xiao et al. Oncolytic viruses: advanced strategies in cancer therapy
CN101565718A (zh) 三靶向嵌合型溶瘤腺病毒Ad5/F11载体的构建方法及其应用
Shen et al. Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene
Yoon et al. A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth
WO2022107705A1 (ja) 新規遺伝子組換えワクシニアウイルス及びその利用
Asavarut et al. Chimeric adeno-associated virus and bacteriophage: a potential targeted gene therapy vector for malignant glioma
Tagawa et al. Cancer therapy with local oncolysis and topical cytokine secretion